Prothena Corporation’s Post

The rise of digital therapeutics has ushered in a new era of healthcare management, and RAVCARE is at the forefront of this transformative shift. By integrating cutting-edge technology, personalized coaching, and evidence-based interventions, digital therapeutics empower patients to take control of their health and improve clinical outcomes. As the healthcare landscape continues to evolve, the role of digital therapeutics in managing chronic diseases is poised to become increasingly prominent. RAVCARE's innovative approach serves as a model for the future of this rapidly advancing field, offering a glimpse into the transformative potential of technology-driven solutions in the management of chronic diseases. #digitaltherapeutics #diabetes #copd #healthyaging #visionhealth #neurodegenerativediseases

The availability and utilization of novel lipid-lowering therapies (LLTs) have led to significant advancements in the clinical management of homozygous familial hypercholesterolaemia (HoFH), according to a study. View the complete article below ⤵️ #HomozygousFamilialHypercholesterolaemia #Cardiovascular #HeartDisease

For #TrialTuesday, Tian Zhang, MD (UT Southwestern Medical Center) leads Alliance A031704 (PDIGREE study) to see how well nivolumab and ipilimumab, followed by nivolumab versus cabozantinib and nivolumab, work in treating patients with untreated advanced #renalcellcancer. To learn more, visit https://lnkd.in/g_vYCUpJ #NCI #NCTN

Anemia poses a significant challenge in lower-risk myelodysplastic neoplasms (MDS), impacting patient outcomes and treatment strategies. While erythropoietin stimulating agents (ESAs) have been a mainstay, responses vary, prompting exploration of new therapies like luspatercept. Ongoing trials and emerging treatments signal a promising shift in anemia management, but challenges in balancing treatment efficacy and toxicity persist. Dive deeper into this evolving landscape in the latest issue of Oncolytics Today. https://lnkd.in/euuUrFTS

The Future of Medicine is Here! Discover how biomarker-driven trials are transforming drug development by tailoring treatments to individual patient characteristics. Learn how this approach is revolutionizing precision medicine and improving patient outcomes. Dive into the world of personalized therapies today! 🔬✨ PrecisionMedicine #BiomarkerTrials #HealthcareInnovation #NotableLabs https://lnkd.in/gyiMpRAn

Up to 60% of clinical trials require biomarker info for patients to participate, but recommendations for biomarker testing to determine eligibility for clinical trials remains inconsistent. Why? We’re exploring this in an abstract and more at #ASCO24.

Learn how the n-Lorem foundation is developing personalized therapies for patients with nano #rarediseases -- at no cost to them or their families. Full video: https://lnkd.in/gDnvhQCE #genetherapy #personalizedmedicine

Alzheimer’s disease is among the world’s most pressing health care challenges, affecting more than 6.9 million people in the US and 40 million globally — numbers that are expected to double by 2040. Health and long-term care costs by then are likely to exceed $760 billion in the US. Our analysis indicates that the market for so-called disease-modifying therapies — as opposed to those that treat just symptoms — can jump to $13 billion by 2030 from $250 million this year. Further growth is possible from drugs attacking earlier stages of the disease, with more than 155 million people worldwide believed to have preclinical Alzheimer’s. Given the unmet need and the lack of a cure, there’s ample room for drugmakers including Roche, AbbVie, Alector, Prothena and Novo Nordisk. Access the full report here: https://bloom.bg/4byuEIM #corporations #healthcare #innovation

Up to 60% of clinical trials require biomarker info for patients to participate, but recommendations for biomarker testing to determine eligibility for clinical trials remains inconsistent. Why? We’re exploring this in an abstract and more at #ASCO24.